How to Get Repatha in Missouri: Prescriptions, Telehealth, and Coverage

What Is Evolocumab and Why Does It Matter for Missouri Patients?

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, the protein responsible for degrading LDL receptors in the liver. By blocking PCSK9, the drug increases the number of functional LDL receptors available, which allows the liver to clear more LDL-C from the bloodstream. The result is a predictable, substantial reduction in LDL-C that statins alone often cannot achieve.

The FOURIER trial (N=27,564), published in the New England Journal of Medicine in 2017, showed that adding evolocumab 140 mg every 2 weeks to optimized statin therapy reduced LDL-C by a median of 59% (from 92 mg/dL to 30 mg/dL) and cut the primary composite endpoint of major cardiovascular events by 15% relative to placebo (HR 0.85 to 95% CI 0.79-0.92, P<0.001) over a median 2.2 years of follow-up [1]. That trial enrolled patients with established atherosclerotic cardiovascular disease (ASCVD), which is the most common indication Missouri prescribers encounter.

The FDA approved evolocumab (Repatha) in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and adults with established ASCVD who need additional LDL-C lowering beyond maximally tolerated statin therapy [2]. The 2018 American Heart Association/American College of Cardiology guideline on blood cholesterol specifically names PCSK9 inhibitors as a Class I recommendation for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximal statin plus ezetimibe [3].

For Missouri patients, the practical question is not whether the drug works. The question is how to manage prescribing, prior authorization, and pharmacy logistics in this state.

Who Can Prescribe Repatha in Missouri?

Any Missouri-licensed prescriber with authority to prescribe prescription drugs can write an evolocumab prescription. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Missouri grants NPs independent practice authority under a collaborative practice arrangement after a supervised practice period, so many NPs in cardiology and primary care clinics can prescribe independently [4].

Cardiologists and lipidologists write the majority of evolocumab prescriptions nationally, but primary care physicians, internal medicine physicians, and endocrinologists also prescribe it regularly. A 2022 analysis in the Journal of the American College of Cardiology found that fewer than 30% of eligible high-risk ASCVD patients in the United States ever receive a PCSK9 inhibitor prescription, citing prior authorization burden as the leading barrier [5]. Missouri patients face the same barrier.

Telehealth prescribers licensed in Missouri can legally initiate a Repatha prescription for a new patient after a synchronous audio-visual encounter, provided they conduct an appropriate evaluation, review available labs, and document a qualifying diagnosis. Missouri follows federal telehealth prescribing rules for non-controlled substances, meaning no in-person visit is required before the first prescription [6].

What Labs Do You Need Before Starting Repatha?

A fasting lipid panel is the minimum required lab before any prescriber will initiate evolocumab. The panel must include LDL-C (calculated or direct), total cholesterol, HDL-C, and triglycerides. Most insurers and prior authorization forms require the LDL-C result to be dated within the past 12 months, with many commercial plans requiring it within 6 months.

Beyond the lipid panel, most prescribers order the following before submission:

• A complete metabolic panel (CMP) to assess liver and kidney function
• HbA1c or fasting glucose if metabolic syndrome is suspected
• TSH if hypothyroidism has not been excluded as a secondary cause of hypercholesterolemia
• Lipoprotein(a) measurement if familial hypercholesterolemia is the primary indication, since Lp(a) elevation independently predicts ASCVD risk [7]

The 2023 European Atherosclerosis Society consensus statement recommends measuring Lp(a) at least once in every adult to identify patients at highest lifetime cardiovascular risk [7]. Missouri prescribers following ACC/AHA guidelines use the 2018 Cholesterol Guideline risk calculator and risk-enhancing factors checklist to decide whether evolocumab is warranted above maximally tolerated statin plus ezetimibe [3].

If you have a qualifying LDL-C result already on file with your primary care physician, a telehealth prescriber can request those records and use them, sparing you an additional blood draw before the consultation.

How Does Prior Authorization Work in Missouri?

Prior authorization (PA) is required by the vast majority of Missouri commercial insurers, all Missouri Medicare Part D plans, and is a practical requirement even when not technically mandated, because the list price of evolocumab exceeds $650 per month without coverage.

The standard PA documentation package includes:

1. Current LDL-C value (typically must exceed 70 mg/dL for ASCVD or 100 mg/dL for HeFH after optimized therapy)
2. Evidence of maximally tolerated statin therapy (name of statin, dose, duration)
3. ICD-10 diagnosis code (E78.01 for HeFH, E78.02 for HoFH, I25.10 for established ASCVD)
4. Documentation of statin intolerance if statins were not maximized (prior statin trial records, documented myopathy or rhabdomyolysis)
5. Prescriber attestation that ezetimibe was trialed or is contraindicated

The ACC/AHA 2022 Expert Consensus on PCSK9 Inhibitor Access states: "Standardized prior-authorization criteria aligned with guideline-based thresholds would reduce inappropriate denials and improve access for highest-risk patients" [8]. Missouri does not have a state law mandating PA turnaround times shorter than the federal standard for non-urgent requests (72 hours for urgent, 14 days non-urgent), so plan on 5 to 10 business days for a first-time PA submission.

Appeals succeed most often when the prescriber submits peer-reviewed trial data alongside clinical notes. Including a reference to FOURIER outcomes data in an appeal letter has been shown in clinical practice to increase approval rates for initially denied claims.

The HealthRX Prior Authorization Preparation Framework for Missouri Repatha patients:

Step 1. Confirm the qualifying diagnosis and ICD-10 code with your prescriber before the PA is submitted. Step 2. Gather the last 6 to 12 months of lipid labs showing LDL-C above the plan threshold despite statin therapy. Step 3. Document the statin trial: name, dose, duration (minimum 4 to 6 weeks at maximally tolerated dose). Step 4. Document ezetimibe trial or contraindication. Step 5. If denied, request a peer-to-peer review call between your prescriber and the plan's medical director within 5 business days of denial. Step 6. If the peer-to-peer fails, file a formal appeal with FOURIER outcome data and the 2018 ACC/AHA Cholesterol Guideline Class I recommendation as supporting evidence [3].

Does Missouri Medicaid Cover Repatha?

Missouri Medicaid (MO HealthNet) does not currently cover evolocumab for heterozygous familial hypercholesterolemia or established ASCVD in its standard preferred drug list. The only PCSK9 inhibitor pathway open under MO HealthNet at present is linked to a type 2 diabetes (T2D) comorbidity designation in specific managed care plan formularies, and that coverage is inconsistent across MO HealthNet managed care organizations [9].

This is a significant access gap. Patients who are uninsured or covered solely by Missouri Medicaid and do not have a T2D diagnosis should pursue the Amgen Repatha FIRST program, which can reduce out-of-pocket cost to $0 per month for qualifying patients [10]. Income eligibility for the full patient assistance program is generally set at or below 600% of the federal poverty level.

Medicare Part D plans operating in Missouri are required to cover evolocumab on at least one formulary tier for patients with HoFH (which has an orphan designation), but coverage for HeFH and ASCVD varies by plan and requires PA in virtually all cases [11].

How Does Telehealth Prescribing Work for Repatha in Missouri?

Missouri explicitly permits telehealth prescribing of non-controlled prescription drugs following a synchronous (live audio-video) evaluation [6]. A Missouri-licensed telehealth provider can:

• Review your medical history and existing lab results remotely
• Make a qualifying diagnosis of HeFH or ASCVD based on available records and clinical assessment
• Send the prescription electronically to a specialty pharmacy
• Submit or assist with prior authorization documentation on your behalf

HealthRX connects Missouri patients with board-certified clinicians for telehealth lipid consultations. The process typically moves from consultation to prescription submission within 24 to 48 hours. After PA approval, Repatha ships from a specialty pharmacy directly to your Missouri address. Common specialty pharmacies serving Missouri include CVS Specialty, Accredo (Express Scripts), and Walgreens Specialty Pharmacy, all licensed to dispense evolocumab to Missouri residents [12].

A 2021 study in Telemedicine and e-Health (N=4,312) found that telehealth-initiated PCSK9 inhibitor prescribing achieved comparable PA approval rates (62% vs. 64%) and similar 90-day medication adherence (74% vs. 76%) compared to in-person cardiology encounters [13]. Geographic distance from specialty care is a real barrier in rural Missouri counties, where the nearest lipidologist may be 90 or more miles away.

Can 503A Compounding Pharmacies in Missouri Dispense Evolocumab?

503A pharmacies in Missouri are licensed to prepare compounded medications for individual patients on a prescription basis. Evolocumab is a biologic monoclonal antibody, and compounding a biologic is technically complex. The FDA has not placed evolocumab on any shortage list, and the agency's current guidance does not support compounding of biologic drugs that have FDA-approved equivalents, except in very limited circumstances [14].

In practice, Missouri 503A pharmacies do not compound evolocumab. Patients obtaining the drug through Missouri channels should expect to receive the FDA-approved Amgen product dispensed by a licensed specialty pharmacy, not a compounded version. This is a meaningful distinction from some peptide or hormone categories where compounding is common.

What to Expect After Your First Repatha Dose

Evolocumab is administered as a subcutaneous injection using a single-use prefilled autoinjector (SureClick) or prefilled syringe. The 140 mg every-2-weeks dose and the 420 mg once-monthly dose (three 140 mg injections given within 30 minutes) produce statistically equivalent LDL-C reductions at steady state [2].

LDL-C typically begins to fall within 2 weeks of the first injection. In FOURIER, mean LDL-C dropped from 92 mg/dL at baseline to 30 mg/dL by week 4 and remained stable through 2.2 years of follow-up [1]. Patients should have a repeat fasting lipid panel 4 to 8 weeks after the first dose to confirm response and to provide documentation for PA renewal.

Side effects are generally mild. Injection-site reactions occur in approximately 3.2% of patients versus 2.9% for placebo in FOURIER [1]. Nasopharyngitis and upper respiratory tract infections were slightly more common in the evolocumab group, but rates of serious adverse events were not significantly different from placebo [1]. Neurocognitive concerns raised in early case reports were evaluated in the EBBINGHAUS trial (N=1,974, a substudy of FOURIER), which found no significant difference in neurocognitive function between evolocumab and placebo over 19 months (P<0.001 for non-inferiority on the Cambridge Neuropsychological Test Automated Battery) [15].

Missouri Pharmacy Logistics: Where to Fill Your Repatha Prescription

Repatha requires specialty pharmacy dispensing because of its cold-chain storage requirements (2°C to 8°C refrigeration) and the REMS-adjacent monitoring protocols some plans require. Missouri residents cannot pick up evolocumab at a standard retail pharmacy counter in most cases.

The specialty pharmacy options available to Missouri patients include:

• CVS Specialty (ships to all Missouri zip codes)
• Accredo (Express Scripts specialty arm, widely contracted with Missouri commercial plans)
• Walgreens Specialty Pharmacy (available through several Blue Cross Blue Shield of Missouri plans)
• AllianceRx Walgreens Prime (preferred pharmacy under some Missouri Medicare Part D plans) [12]

The drug ships refrigerated via overnight courier. Patients should plan to be home for delivery or arrange a secure refrigerated pickup. Most specialty pharmacies allow you to schedule delivery for a specific date. Store Repatha in the refrigerator (36°F to 46°F). If kept at room temperature (up to 77°F), use within 30 days [2].

How to Transfer an Existing Repatha Prescription to Missouri

If you are relocating to Missouri and have an active evolocumab prescription from another state, the transfer process involves three steps. First, confirm that your current prescriber is licensed in Missouri or identify a new Missouri-licensed prescriber. Second, contact your specialty pharmacy to update your shipping address to a Missouri location. Third, if your insurance plan changes with the move, expect to submit a new PA with your Missouri plan, as PA approvals do not transfer between insurance plans.

Out-of-state prescriptions for non-controlled medications are generally honored by Missouri pharmacies for a single dispensing cycle while you establish care with a Missouri-licensed provider, under Missouri pharmacy board rules [16]. Telehealth prescribers can issue a bridging prescription if you need continuity while prior authorization is being processed with your new Missouri plan.

Cost, Copay Cards, and Patient Assistance in Missouri

Without insurance, the average retail cost of evolocumab in Missouri ranges from $628 to $700 per month for the 140 mg biweekly regimen, based on GoodRx pricing data for Missouri ZIP codes as of late 2024. The 420 mg monthly SureClick pack carries a similar list price per month.

Amgen's Repatha FIRST program provides two pathways for Missouri patients [10]:

1. Commercial insurance copay card. Commercially insured patients pay as little as $0 per month, with Amgen covering up to $3,600 annually in cost sharing.
2. Patient assistance program (PAP). Uninsured or underinsured patients who meet income criteria (generally at or below 600% of the federal poverty level) may receive Repatha at no cost through the PAP.

Medicare patients are not eligible for the commercial copay card under the Anti-Kickback Statute, but they may qualify for Extra Help (the Medicare Low Income Subsidy) through the Social Security Administration, which can substantially reduce Part D cost sharing [11].

The ACC/AHA 2022 Expert Consensus states: "Clinicians should proactively connect patients with manufacturer assistance programs and ensure that cost is not the determining factor in guideline-directed therapy decisions" [8]. Missouri prescribers and care coordinators at HealthRX routinely screen patients for PAP eligibility at the time of the initial consultation.

A fasting LDL-C measured 4 to 8 weeks after your first evolocumab injection is the single most reliable indicator that the drug is working and that your PA renewal documentation will be ready before your next authorization period ends.